If you want to distinguish your goods, services or both from those of another company, you may need a trademark or trade name. Find out what they are, what their registration procedure is and what it involves.
Information on the deadlines for filing applications for transformation of European Union trademarks into Spanish national trademarks. See more
If you have a new device, product or procedure that solves a technical problem or has a practical advantage, there are different ways to protect it in Spain and other countries. Find out how.
Does your innovation lie in the aesthetics, ornamentation or appearance of your product? Protect it through industrial design. Find out what rights registration confers and how to proceed.
Patents published worldwide are a valuable source of scientific, technical and commercial information.
El Bono 3 del Fondo para PYMEs 2025, que cubre la elaboración de Informes Tecnológicos de Patentes (ITP) y Búsquedas Retrospectivas se cerrará el lunes 10 de febrero de 2025 al cierre de la jornada laboral. Próximamente se informará sobre su reapertura. Puede consultar más información aquí.
If you are an entrepreneur or a company and you want to boost and improve the profitability of your business by adequately protecting the intangible assets of your organisation, in this space you will find what you need.
207
results.
Updated on
18/05/2025 [06:53:00]
Results 175 to 200 of 207
Absstract of: EP4548757A1
The present invention relates to a method for producing a nonhuman primate animal model of cerebral infarction, comprising administering endothelin to basal ganglia and thalamic region of a nonhuman primate, and thereby inducing basal ganglia damage, thalamus damage, and internal capsule damage; and a pharmaceutical composition for the treatment of cerebral infarction at a subacute to chronic stage, penetrating branch infarction, or cerebral infarction having brain damage in a penetrating branch territory, comprising a NeuroD1 protein or a polynucleotide encoding the NeuroD1 protein.
Absstract of: US2024042070A1
Described herein are compositions and methods for treating cancer using a RIG-I agonist precursor comprising single-stranded 5′ uncapped triphosphate or biphosphate antisense oligonucleotide having a sequence complementary to an endogenous miRNA; optionally wherein the compositions and methods comprise a nanoparticle for targeted delivery of the RIG-I agonist precursor and a radiolabel to a tumor micro environment.
Absstract of: WO2024006410A1
This document relates to methods and materials for treating vascular stenosis. For example, nanoparticles (e.g., poly lactic-co-glycolic acid (PLGA) nanoparticles) including one or more inhibitors of a monocyte chemoattractant protein (MCP) polypeptide (e.g., bindarit) are provided. In some cases, a composition (e.g., a hydrogel composition) including one or more nanoparticles including one or more inhibitors of a MCP polypeptide (e.g., bindarit) can be placed in direct contact with an adventitia of one or more blood vessels (e.g., one or more blood vessels at risk of stenosis formation) within a mammal (e.g., a mammal such as a human that underwent an angioplasty) to reduce or eliminate stenosis formation in the blood vessel(s).
Absstract of: US2025099394A1
The present invention provides a lipid nanoparticle (LNP) formulation comprising at least one sialic acid (SA)-containing lipid. The LNP formulation is capable of effectively binding cell surface Siglecs, transfecting certain cells in vitro and targeting certain cells in vivo. The present invention also provides methods of using the LNP compositions described herein for pharmaceutical applications. For example, the LNPs provided herein are useful for the intracellular delivery of a nucleic acid therapeutic to a subject.
Absstract of: AU2023300349A1
Provided is a lipid formulation capable of forming a lipid-based nanoparticle comprising an ionizable lipid to phospholipid molar ratio of 0.1 - 1.30 of in association with a nucleic acid payload, and in some embodiments, a stabilizing agent. In embodiments, the nucleic acid payload is a vaccine genetic element.
Absstract of: MX2024000185A
There are provided improved amphiphilic comb polymers, comprising a hydrophilic backbone with regularly-spaced pendant hydrophobic moieties, having well-controlled molecular weights, structures, and end groups. The polymers self-assemble into core-corona nanoparticles in aqueous environments, which are capable of disrupting viral coat proteins, and which are capable of encapsulating antiviral drugs and prodrugs. Regularly-spaced targeting moieties optionally mediate the adherence of the nanoparticles to the viral coat. The compositions of the invention are useful as treatments for viral infection, including infections with SARS-CoV-2.
Absstract of: WO2024003363A1
The present invention relates to a method and compositions for optimized cytosolic delivery of active agents, in particular nucleic acids, using a specific class of cationic amphiphilic compounds. The method and compositions of the invention enhance intracellular release of the agents and can be used for the treatment of various disorders.
Absstract of: WO2024006960A1
The present disclosure relates to compositions comprising lipid nanoparticles for delivering nucleic acid molecules into cells. Also included are methods for producing and using such compositions.
Absstract of: EP4548973A2
A pharmaceutical composition including insulin, Docosahexaenoic acid (DHA) and coenzyme Q10 and methods of manufacturing and using the composition are provided.
Absstract of: CN119931074A
本发明公开了一种纳米金属有机框架化合物及其制备方法和应用。所述纳米金属有机框架化合物包括从内向外依次设置的内核、包覆于内核表面的第一壳层，以及化学修饰并包覆于所述第一壳层表面的第二壳层，所述内核包括铜‑半胱胺纳米颗粒，所述第一壳层包括2‑甲基咪唑锌盐，所述第二壳层包括透明质酸。本发明提供的纳米金属有机框架化合物材料具有光敏特性及酶催化活性，并且可以有效靶向肿瘤细胞。并且整个制备过程简单、环保，利于规模化生产，为癌症的治疗提供了新的思路和方法。
Absstract of: AU2023347022A1
Disclosed is a lipid nanoparticle (LNP) encapsulating a nucleic acid cargo preferably comprising messenger ribonucleic acid (mRNA). The LNP comprises at least a cationic lipid fraction, and a stabilizer fraction. The stabilizer fraction preferably comprises at least one polyethylenglycol (PEG) lipid. Furthermore, the LNP comprises at least one glycerol dialkyl glycerol tetraether (GDGT) lipid, as obtained e.g. from archaea of the genus Sulfolobus, optionally among other ether lipids. Also disclosed is a pharmaceutical composition comprising the LNP, such as an mRNA vaccine.
Absstract of: CN119925306A
本发明公开了一种环黄芪醇‑花型乳糖在制备治疗急性病毒性心肌炎药物中的用途。本发明公开了黄芪有效成分环黄芪醇治疗病毒性心肌炎，以纳米载体运载环黄芪醇治疗病毒性心肌炎，除了能够通过调节免疫系统抑制机体免疫风暴外，还可能通过激发靶器官细胞内在防御机制活力发挥抗病毒作用，对实验性柯萨奇B3病毒(CVB3)小鼠心肌炎模型具有显著的改善作用。
Absstract of: AU2023317842A1
The present invention relates to compositions that can deliver therapeutic molecules such as nucleic acids to mammalian cells, and to the human and animal body and methods of preparing and using the same. The compositions comprise nanoparticles comprising a peptide dendrimer, a nucleic acid and a lipid. The compositions of the invention find utility in the field of medicine, such as for treating cancer and autoimmune diseases.
Absstract of: CN119925300A
本发明属于抗膀胱癌药物技术领域，公开了一种IL 12mRNA脂质纳米粒，包括IL 12mRNA和用于递送IL 12mRNA的载体，所述的载体包括一种或多种氨基酸生育酚氧烷酯或其药学上可接受的盐。以及公开了该脂质纳米粒的制备方法和在制备抗膀胱癌药物上的应用。该脂质纳米粒以氨基酸生育酚氧烷酯作为递送IL 12mRNA的可离子化脂质分子载体，有效的将IL 12mRNA递送到肿瘤细胞内，避免了mRNA被酶降解的风险，同时，在小鼠膀胱癌治疗组中发挥抗肿瘤作用，抑制了癌细胞的增长，并且具有较好的生物安全性。
Absstract of: CN119925299A
本发明涉及医用材料技术领域，尤其涉及一种抗肿瘤疫苗及其应用。所述抗肿瘤疫苗包括抗肿瘤纳米颗粒；所述抗肿瘤纳米颗粒包括：用于编码质膜膜泡关联蛋白的核酸、阳离子脂质和非阳离子脂质。本发明经过研究发现，基于肿瘤血管内皮细胞上特异性表达的抗原分子（质膜膜泡关联蛋白）制备的抗肿瘤疫苗可以高效激活肿瘤患者的免疫抑制微环境，诱导生成大量杀伤性T细胞，其能够靶向识别并杀伤具有PLVAP蛋白表达的肿瘤血管内皮细胞，高效破坏肿瘤血管，在抗肿瘤生物材料领域具有重要价值。
Absstract of: CN119930762A
本公开涉及非洲猪瘟病毒EP153R蛋白的免疫原性片段、重组蛋白、免疫原性组合物及其用途。本公开提供的非洲猪瘟病毒EP153R蛋白的免疫原性片段或其具有免疫原性的变体能够大大提高表达量，同时保留了强免疫活性。
Absstract of: CN119925303A
本发明提供一种纳米材料及其制备方法，所述所述纳米材料是以白蛋白(BSA)为模板，触发BSA与多酚(TA)的氧化偶联，形成以铜硫化物为核心，白蛋白与多酚为外壳的有机无机杂化纳米材料(TA‑BSA@CuS)。并包裹过表达Gas6的鼻咽癌细胞膜，形成Gas6细胞膜/TA‑BSA@CuS纳米材料，该材料能够有效的抑制肿瘤的肺转移。
Absstract of: CN119925305A
本发明涉及药物制剂技术领域，具体涉及一种积雪草苷纳米结构脂质载体及其制备方法。该纳米结构脂质载体是由水相和油相混匀后均质而成，其中水相是含有乳化剂的溶液，该油相是含有积雪草苷、固体脂质和液体脂质的混合液，通过熔融乳化‑高压均质法制成。本发明制备的积雪草苷纳米结构脂质载体具有粒径小、包封率高和稳定性好的优势，且制备方法简单可控，重复性好，解决了积雪草苷不易溶于水和生物利用度低的难题，为积雪草苷提供了一种可供选择的递送系统。
Absstract of: CN119925644A
本发明涉及超声分子影像学技术领域，涉及一种仿生抗炎纳米超声造影剂及其制备方法和应用。所述仿生抗炎纳米超声造影剂以负载雷帕霉素的红细胞膜为壳膜材料，内部包裹有负载TAT肽、siRNA的微小介孔二氧化硅及全氟戊烷或全氟己烷。制得的仿生抗炎纳米超声造影剂生物安全性高，能够在体内高效转运siRNA和雷帕霉素，实现无创靶向抗炎治疗。
Absstract of: CN119925302A
本发明公开了一种基于褐藻多酚纳米营养载体的制备及应用研究，属于纳米材料的制备技术领域。具体包括：将精氨酸溶于水中，接着加入褐藻多酚，得到混合液；将PEG溶于PBS中，得到PEG溶液；将PEG溶液加入到混合液中进行搅拌，并加入过氧化氢反应，加入乙酸继续反应，经过流水透析、真空干燥得到褐藻多酚纳米粒子。本发明实现了褐藻多酚这类天然多酚在溶解度、稳定性方面的限制，为天然多酚的实际应用提供了有力的技术支撑；所合成的纳米粒子在以脂多糖诱导的巨噬细胞炎症反应中表现出优异的抗炎特性，在DSS诱导的小鼠溃疡性结肠炎展示出优异的抗氧化与抗炎能力，为有效预防溃疡性结肠炎提供了一定的理论基础。
Absstract of: CN119925584A
本发明涉及动物疫苗制备技术领域，公开了一种鸡支原体病灭活疫苗的制备方法，包括以下步骤：支原体菌株的培养：将鸡支原体菌株接种至SP4培养基中，培养温度为35～39℃，培养时间为48～72小时，收集支原体菌体；灭活与抗原保护：在支原体悬液中加入灭活剂和抗原保护剂进行灭活与抗原保护反应，反应温度为25～37℃，反应时间为3～6小时；纳米递送系统的制备：通过壳聚糖与海藻酸钠的复合结构制备纳米颗粒递送系统。通过动态灭活与抗原保护协同技术方案，通过在灭活过程中同步引入聚赖氨酸、谷氨酰胺和精氨酸的抗原保护体系，显著避免了灭活剂对支原体抗原表位的破坏。
Absstract of: WO2024028492A1
The present invention relates to methods of determining the efficiency of RNA encapsulation in lipid nanoparticles (LNPs). In some embodiments, methods according to the present invention comprise a step a) of contacting a sample comprising RNA encapsulated in LNPs with a first fluorophore and a second fluorophore, thereby forming fluorophore-RNA complexes, and a step b) of detecting the fluorescence signals of the complexed first and second fluorophore, wherein the first fluorophore permeates the LNPs and wherein the second fluorophore does not permeate the LNPs.
Absstract of: CN119925291A
本发明涉及细胞膜仿生递药技术领域，具体涉及靶向动脉粥样硬化病灶的细胞膜仿生递药系统的制备方法及其产品和应用，步骤为先培养巨噬细胞，提取和纯化巨噬细胞膜，并加入酶抑制复合物并储存；将储存的巨噬细胞膜利用带有纳米膜的微型挤压机反复挤出获得巨噬细胞膜微囊；利用溶剂挥发法制备基于PEG‑PLGA的载药纳米颗粒；最后将巨噬细胞膜微囊和载药纳米颗粒分别从微流控电穿孔芯片的两个入口注入，再施加两段式交变电场，处理后得到分散均匀的混合液，再将该混合液采用带有纳米膜的微型挤压机共挤出，即可。本发明制备的细胞膜仿生递药系统具有生物可降解、药物缓释、长效循环、结构稳定、主被动双重高效靶向的优势，能有效抑制动脉粥样斑块的发展。
Absstract of: CN119924515A
本发明涉及纳米载体技术领域，公开了负载姜黄素的核壳型纳米颗粒及其构建方法，包括以下步骤：将玉米醇溶蛋白溶于乙醇溶液中，并添加还原性糖进行反应，然后进行压差震荡解聚处理，得到玉米醇溶蛋白溶液；向玉米醇溶蛋白溶液中加入姜黄素，得到负载姜黄素的玉米醇溶蛋白溶液；然后加入CaCl2溶液和果胶溶液混合，滴入磷酸盐溶液，进行反应，形成沉淀；经水洗、离心、冷冻干燥，得到负载姜黄素的复合纳米颗粒。本发明采用上述的负载姜黄素的核壳型纳米颗粒及其构建方法，以玉米醇溶蛋白为核，磷酸钙为壳，并通过配位络合作用在外部包裹果胶，使纳米颗粒提高稳定性的同时，具备pH响应特性。
Nº publicación: CN119931037A 06/05/2025
Applicant:
中国科学院长春应用化学研究所
Absstract of: CN119931037A
本发明属于生物医药领域，尤其涉及一种脂质‑亲水聚合物及其制备方法和应用。本发明提供的脂质‑亲水聚合物具有式（I）所示结构，式（I）中，R1为聚合度在20~50的亲水聚合物基团，R2为C2~C4烷基，R3为C2~C4烷基，R4为含有C10~C22单尾或C10~C22双尾的疏水性脂质基团，L1为酯键，L2为酰胺键或酯键。本发明通过分子结构设计，在亲水聚合物与脂质之间引入缩硫酮敏感化学键，获得了可断裂型脂质‑亲水聚合物。在此基础上，通过提升脂质‑亲水聚合物在脂质纳米颗粒中的摩尔百分占比，能够在增强脂质纳米颗粒稳定性的同时实现高效转染。#imgabs0#式（I）。
BOPI
Electronic site
